Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference

Rhea-AI Summary

Beam Therapeutics (Nasdaq: BEAM) announced the participation of CEO John Evans in a fireside chat at the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 8:00 a.m. ET. The event will be accessible via a live webcast on the investor section of the company’s website, www.beamtx.com, and will be archived for 60 days post-event.

Beam Therapeutics specializes in precision genetic medicines utilizing base editing technologies to develop targeted genomic therapies, positioning itself as a leader in the biotech sector.

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, Oct. 5, 2020 at 8:00 a.m. ET.

The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit www.beamtx.com.

Contacts:

Investors:
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

Media:
Dan Budwick
1AB
dan@1abmedia.com

FAQ

When is Beam Therapeutics' CEO participating in the Chardan Virtual 4th Annual Genetic Medicines Conference?

CEO John Evans will participate in the conference on October 5, 2020, at 8:00 a.m. ET.

How can I access the fireside chat by Beam Therapeutics at the conference?

The fireside chat will be available via a live webcast on Beam Therapeutics' investor website at www.beamtx.com.

How long will the webcast of the Beam Therapeutics fireside chat be available?

The webcast will be archived for 60 days after the presentation.

What technology does Beam Therapeutics focus on in their genetic medicine development?

Beam Therapeutics is focused on precision genetic medicines using base editing technologies.

What is the stock symbol for Beam Therapeutics?

The stock symbol for Beam Therapeutics is BEAM.